Andrea Necchi, Associate Editor @ Journal of Clinical Oncology, shared on X:
” Looking forward to showcase at ESMO25 our further research on novel neoadjuvant therapies in muscle-invasive bladder cancer
- LBA110: GDFather-NEO trial tested for the first time GDF15 targeting in combo with Nivo | long-term follow-up results of the Ph1 trial are impressive in metastatic UC and will also be updated by Ignacio Melero in another PP session (abstract 1513O)
- Primary results of #Sunrise4 will show the benefit of integrating ctDNA and utDNA in predicting pCR Response and RFS after TAR200+cetrelimab.”
Other articles from Andrea Necchi.
